Introduction
Women's cancer (breast, cervical, ovarian and uterine cancers) cause in excess of 1 million deaths each year worldwide; about three times more deaths each year than maternal mortality. 1 The majority of these cancer deaths will occur in Low and middle income countries. 1 India's cancer burden, currently estimated at over 1.5 million new cases is predicted to nearly double in the next 20 years , with age-adjusted mortality rates of 64.5 per 100,000 (GLOBOCAN 2012). 2 3 The burden among Indian women is higher than men, in marked contrast with the worldwide picture of cancer in which the overall age standardized cancer incidence rate is almost 25% higher in men than in women. 4 Cumulatively, breast, cervical, ovarian and uterine cancer account for more than 50% of cancers in women in India. (Figure 1 ) Whilst cancer incidence rates are relatively low in India, cancer mortality rate is very high, at 68% of the annual incidence. This ratio indicates that fewer than 30% of Indian patients with cancer survive 5 years or longer after diagnosis. 5 In view of the limitations in the available data, (including low coverage, particularly in rural areas), the true proportion could be significantly lower. By contrast, in North America and Western Europe, overall 5 year survival for all cancers is about 60%. Delayed diagnosis and inadequate, incorrect or suboptimum treatment (including patient inability to access or complete appropriate therapies) are significant causes of poor cancer survival in India. 6 7 Hitherto unidentified differences in tumour biology may also contribute to poorer survival. The delivery of affordable and equitable cancer care is thus one of India's greatest public health challenges. 8 Since the sequencing of the human genome in 2001, 9 10 applications of advancing technologies such as massively parallel sequencing have transformed our understanding of the genetic and environmental drivers of cancer. [11] [12] [13] The under $1000 dollar whole genome sequence is now a reality. Insightful applications of this technology have the potential to transform health by delivery of 'precision medicine' or 'individualized medicine'. How can these technologies be best harnessed to provide health care solutions at scale and at budget for a country of 1.2 billion people that has huge diversity and a fragmented healthcare system? What research programs are necessary to answer India specific questions and build capacity for innovative solutions using these technologies?
Search strategy and Selection criteria
We performed a systematic search of published literature in English using the terms 'India', 'cancer', 'genomics', 'Genome-wide association studies' ( GWAS), search date any published to December 2016. We searched Pubmed and Google. Papers were selected for inclusion if they were reviews or original research with data relevant to the application of genomics in women's cancer 
Challenges from women's cancer in India
Changing demographics in India including rapid economic growth, increasing life expectancy, declining mortality from communicable diseases and changes in lifestyle are mirrored by a change in cancer profiles. 14 Welfare, Government of India has recently launched the operational guidelines for screening and prevention of three common cancers oral, breast and cervical cancer. 17 There are also substantial variations in health systems, access and coverage between the various states in India.
Rationale for cancer genomics research in India -differences in cancer biology and epidemiology
Significant clinical differences in cancer behaviour demonstrate that data derived in the West cannot be applied without modification to India. For instance, oral cancer occurs more frequently in Indian populations; nearly 73.4% of Head and neck cancer in India is from gingivobuccal origin as compared to 22% of cancer in the West and is associated with extensive tobacco and betel nut chewing practices. 18 For breast and ovarian cancers, the peak age of onset in Asian countries appears to be a decade younger (45-50 years) than the peak age in the west (> 60). 19 By contrast almost half of all breast and ovarian cancers in the UK will be diagnosed in women over the age of 65 years. 20 These epidemiological differences may be underpinned by a difference in biologyincidence of triple negative breast cancer has been reported as higher in India. 19 21 Multicenter large scale studies with standardized histopathology are needed to confirm these observations (Box1)
These findings have social and economic ramifications but also practical implications for diagnosis and management. For instance, the accuracy of mammography in Indian women as a screening tool may be lower due to differences in breast architecture in younger women. A key deficit previously highlighted is the lack of cancer research to guide early detection, prevention, and treatment strategies tailored to India rather than international guidelines suited to implementation in high income countries. 22
Significant regional differences also exist within India with variations in cancer type and distribution between the different Indian states. Total cancer rates in population-based registries vary by more than 6-fold across the country , and more than 30-fold differences for sites such as the (Figure 3 )
These epidemiological differences may well be underpinned by a difference in cancer genomics and biology, differences in prevalence of cancer risk factors, or both, and efforts to unravel these will be absolutely vital to effective cancer control and prevention efforts. (Box-1)
Applications of cancer genomics

Population Diversity and Cancer Genomics
India is the sixth largest country in size and is the second most populous country in the world at 1.2 billion. (http://www.censusindia.gov.in). The majority of the modern Indian population comprises a mix of two large genetically divergent and heterogeneous population groups that mixed in ancient times (about 1200-3500 BC), known as Ancestral North Indians (ANI) or the Caucasoids and Ancestral South Indians (ASI) or the Australoids. 23 Overall there are more than 4000
anthropologically distinct groups and 22 languages with various dialects in this diverse nation. 24 This diversity is enhanced by caste and religion based boundaries and consanguinity, making clusters of specific diseases and founder mutations a possibility. 23 This genetic diversity is represented in an extremely limited way in current bioinformatics databases, posing challenges for research and meaningful clinical interpretation. For instance the Exome Aggregation Consortium which seeks to aggregate and harmonize exome sequencing data has limited representation of population of Indian origin. 25 An excellent resource is the Indian Genome Variation Consortium project which has studied polymorphisms in 900 genes from 55 different population groups (http://www.igvdb.res.in/). This forms an important database for design of further studies of multifactorial as well as single gene disorders. 26 Another excellent advance is the TMC-SNPdb: an Indian germline variant database derived from whole exome sequences representing 114 309 unique germline variants-generated from whole exome data of 62 normal samples derived from cancer patients of Indian origin. 27 Even with these advances, population level sequencing or genotyping data for India is quite limited at present, with only a few hundred whole genome datasets among various institutions, and some larger array-type studies to draw upon. The 100,000 Asian Genomes Project will give access to the largest amount of India Sequence data in future and is in planning stages. 28 A truly representative pan Indian genomic variant data resource across diverse ethnic groups is a key challenge to be overcome if implementation of genomics to improve clinical care in India is to be a reality. 29 ( Box-
1)
Cancer being a disease at a genome level, every patient has a unique profile, at both pathological and molecular levels. However, shared germline mutations are known to confer susceptibility risk.
This has inspired the design of linkage analysis studies to identify regions of the genome shared across families carrying the same phenotype, most successful in the identification of the BRCA1 and BRCA2 genes. 30 31 Such approaches however cannot explain the entire incidence, and the focus has since shifted to association studies of common variants, with potentially modest effect. These genome-wide association studies (GWAS) are based on more, albeit less informative, markers, shared further generations back than in linkage studies. This allows for the analysis of larger cohorts without the need to collect familial information and has led to hundreds of studies being performed across the world resulting in the association of thousands of genetic loci with numerous phenotypes.
Famously genetic background could link up geographical information, especially across the numerous GWAS performed in Europe. 32 This underlying structure of the data admirably reflects population diversity at a genetic level; conversely this also raises concerns about the validity of GWAS findings in populations distinct from the original region of discovery and undermines associations where cases and controls had different backgrounds.
Carefully elucidating the effect of population diversity in India through well planned GWAS studies is likely to yield valuable fresh insights into disease aetiology and responses to drug therapy.
Recently the first such study in an Indian population to examine a large number of GWASidentified breast cancer risk loci has been published. 33 Using such cohorts especially enriched for a given phenotype, may maximize the information and find valuable associations with key genes even with limited cohort size. 34 Furthermore, if appropriately recognized, limited population heterogeneity is an opportunity to increase the power of discovery. 35 
Familial cancer in women
Approximately 10% of women with breast cancer, 20% with ovarian cancer and up to 9% with uterine cancer display inherited mutations in germline DNA as reported in studies performed in the West. [38] [39] [40] Importantly, these mutations are also identified in 'unselected women' with cancer that is those without a family history of cancer or early age of onset. 41 [44] [45] [46] While population-based mammography screening is unlikely to be useful in India at present, targeted screening efforts using mammography in these 'at risk' populations, with careful age constraints on publically available programs may prove cost effective and reduce mortality. 47 We also highlight a note of caution here -that screen-detected cancers may have a different genomic and phenotypic presentation than clinically detected cancers. Cancers that present clinically are more commonly biologically aggressive cancers, more commonly basal or triplenegative tumours, which screen detected (clinically occult) cancers are more commonly ER+ more biologically favourable variants.
In this context, it would be helpful to investigate the differences between screen detected cancers and clinically detected cancers in the South Asian populations who have migrated to high income countries. ( Box1) Data on this is currently limited, as unfortunately, South Asian immigrants settled in the United Kingdom and North America have lower screening uptake rates for breast, cervical and colorectal cancers 48 Furthermore, considerable diversity in mutation profiles by ethnicity exists in the BRCA 1 and 2 genes. 49 Whilst substantial information about the prevalence and spectrum of BRCA mutations exists in European and North American populations information is lacking in other populations, including the Indian population. Using data from Caucasian populations to interpret data from non -Caucasian populations can be highly misleading and lead to misdiagnosis. 50 In addition, the inherited risk of breast and ovarian cancer risks vary by type and location of BRCA1/2 mutations, making it vital to characterise the spectrum of mutations by ethnicity. 51 Current data on the prevalence and nature of BRCA mutations and other inherited cancer predisposing genes in the Indian population is valuable but limited to single centre studies, relatively small sample sizes, restricted to selected women with strong family history of cancer, using older technologies e.g. Sanger sequencing. 52 53 More recently two pivotal studies using panel testing and Next generation sequencing have been published. 54 55 The first study screened 91 patients with family history of Hereditary breast or ovarian cancer or early onset of cancer from Southern India, previously tested negative by an earlier PCR-dHPLC (PCR-denaturing high performance liquid chromatography)-based, by targeted resequencing of a multi-gene panel and reported a mutation rate of 26.4% (24/91). The second study identifies up to 36% prevalence of pathogenic mutations in breast and ovarian cancer susceptibility genes in women tested with a private provider, including some sporadic patients. 54 55 There is an urgent unmet need for large scale studies recruiting unselected women with Breast, ovarian and uterine cancer from across the different regions of India, from both urban and rural distributions, carefully annotated with clinical, pathological, survival data, tested with pan cancer panels using NGS to characterize the prevalence and spectrum of mutations and variants of uncertain significance in Indian women. In order to tease apart intrinsic biological differences from environmental factors, and to assess the interplay of the two, it is essential that data should be also collected on epidemiological characteristics and environmental exposures to potential carcinogens.
(Box1)
Human Papilloma virus (HPV) infection and Cervical cancer
As previously discussed, Cervical cancer incidence rates differs widely across regions in India.
Furthermore, HPV variants differ in oncogenic potential, because of differences in biological, biochemical effects. 56 The oncogenicity of distinct HPV variants may also differ between geographical regions because of differences in the population related to the distribution of HLA alleles. 57 
Influence of environmental risk factors
Genetic heterogeneity between endogamous groups within India is at least 3-fold higher than that observed between European populations, which is attributable to different waves of migration and admixture. Further, the genetic variants interact with the diverse environmental factors within India and exhibit such diverse effects across different geographic regions and ethnic groups.
Wide variations in cancer types and incidence between various regions in India maybe due to
genetic variations in a proportion of patients, however it is also highly likely that environmental factors, lifestyle and habits play a bigger role.
For instance, significant variations in the cancer type and presentation are found in the Indian subcontinent compared to the rest of the world some of which can be related to specific differences in environmental exposure e.g. in case of oral cancer , which is the predominant cancer type in men in India. Oral cancer predominantly presents as tongue cancer in the West, while in India it predominantly affects the gingivo-buccal region, comprising buccal mucosa, retro-molar trigone and lower gum. This might be related to the chewing betel-quid comprising betel leaf (Piper betle), areca nut (Areca catechu) and slaked lime (predominantly calcium hydroxide), with or without tobacco, is traditional and popular in India and is known to cause oral cancer. 59 Human papilloma virus (HPV) infection is also an established risk factor, with prevalence in oral cancer ranging between 20 and 50% across geographical regions. 60 
Ongoing efforts in cancer genomics in India
Capacity building for research in genomics in India
Capacity building for research in genomics in India will require a multipronged approach, with the need to train scientists in next generation sequencing, bioinformatics and health care providers including clinicians, nurses and counsellors in engaging with informed consenting of patients, nuanced interpretation and communications of results. Ongoing efforts such as the infrastructure to collect large scale prospective clinical, pathological, therapy and survival data such as the National cancer grid will also be vital to this effort. 8 Patient -public engagement by researchers and effective advocacy through patient groups will be pivotal. All these efforts may be enhanced by public-private partnerships.
India's standing as a leader in Information technology, the large pool of graduates trained in the traditionally valued science disciplines and India's demographic dividend may be fortuitous in creating the right conditions to create a genomic powerhouse. The Government of India has launched ambitious initiatives to improve online infrastructure and internet connectivity with 'Digital India' and a commitment to making India the skills capital of the world, 'Skills India' which may facilitate the skilling up of graduates in the relevant disciplines. 65 66 The Government of India has also launched a massive project, called Aadhar, to provide a digital identity based on an individual's fingerprints and retina scans. As of 2016, the program had issued 12-digit identification numbers to 1.1 billion people. 67 These initiatives are pivotal in imagining a future where individuals can carry health data in conjunction with a digital identity.
Whilst advances in massively parallel sequencing have revolutionized our understanding of disease genomics and personalized medicine, it has also unleashed an enormous amount of data, both structured and unstructured, prompting experts and scientists to coin the term "BIG DATA".
These huge data sets have challenged the community to devise new sets of analytical and data access tools. It is important to highlight the lack of experience and expertise in bioinformatics while dealing with analysis of big data in India. There are currently very few islands of excellence where expertise exists to evaluate and meaningfully analyse big data from genomics research. Other areas of deficit include the lack of expertise in statistical genetics, systematic data management, data management of array data and a lack of basic computational facilities required to store and manage There are a range of socio-economic and socio-cultural factors that can also play a role in the variation in site-specific incidence and survival that is observed globally, and by region and race/ethnicity within countries such as India. 72 73 Specifically, barriers to early detection in India stem from factors including low cancer literacy, stigma, fear, health care access and cost of care. 74 A recent review found low literacy for breast cancer awareness in Indian women, including nursing professionals, whose knowledge of risk factors was not aligned with the importance/strength of a risk factor. 75 Cancer mortality patterns reveal the importance of socio-economic determinants including geographical location such as the Northeast or living in rural areas for women or infectious-related cancers, low education and religion. 74 In addition, there is a substantial knowledge deficit on cultural attitudes to genetic testing amongst patients and caregivers as well as the awareness of inherited cancer risk in Indian women. Shyness, fear of cancer, stigma, financial constraints are some of the barriers to early detection of cancer. 79 Qualitative studies to assess the type and magnitude of the various barriers will be important; to ensure that insight gained by cutting edge genomic technologies translates into real benefit in screening, prevention for family members at risk. Studies that promote cancer literacy and understanding social and cultural barriers to cancer prevention will also be important. 80 (Box-1)
Thus, whilst genomics based research may enable a better understanding of ethnic variations in cancer patients in India and enable India specific cost effective interventions, it is only one factor in a much broader framework of cancer control and not likely to be a universal panacea.
Genomics and improving Outcomes from womens cancers
How might a better understanding of Genomics improve outcomes from women's cancer in India given such prevalent sociocultural barriers? Population based screening methods for India may not be affordable or cost effective, given equally competing demands for universal education, sanitation amongst others. However understanding India specific differences through genomics may enable the identification of women at high risk of development of cancer where targeted screening may be cost effective. We need to urgently identify Indian specific genetic/epigenetic biomarkers related to intermediates of breast cancer like mammographic density. These may have potential to be used as biomarkers for early detection at screening stage. Equally a greater understanding of the oncogenicity of HPV variants in Indian woman will help the development of low cost vaccines for cervix cancer. Treatment regimens developed using evidence generated from trials performed on Caucasian women may not be applicable or as effective in a population with such distinct phenotypical differences. Developing evidence based India specific paradigms of screening and management are therefore essential to improving outcomes.
Conclusions
We envisage that genomics technologies harnessed to understand India specific differences in the presentation, epidemiology and clinical behaviour of women's cancer may lead to the development of appropriate cost effective, targeted screening and prevention for women at risk of development of Breast and ovarian cancer, new strategies for prevention in Cervix cancer as well as effective cancer treatment paradigms.
Strong multidisciplinary research teams comprising expertise in clinical studies, genomics, bioinformatics, modeling, qualitative research and public health will need to work collaboratively to harness the immense potential offered by novel next generation sequencing technologies. This will ensure that the benefits from these technologies are harnessed in an evidence based and cost effective way to improve women's health and alleviate cancer burden in India.
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